Gapping up
In reaction to earnings/guidance:
- CTRN +8.3%, LOVE +8%, FLXN +5.3% (guides to Q1 ZILRETTA sales of $24.6 mln), TEAM +3.8% (guides MarQ revs well above consensus, but co believes it's short-term event-driven), SAP +3.4% (raises FY21 outlook reflecting the strong new cloud business performance), BRKR +1.5% (issues upside Q1 revenue guidance), GS +1.5%, PKI +0.9% (issues upside Q1 revenue guidance), WAFD +0.6%
Other news:
- GALT +30.3% (Phase 1 clinical research for Belapectin published in Journal for ImmunoTherapy of Cancer)
- GLSI +15% (announces update of GP2 phase III clinical trial design at the 2021 AACR Annual Meeting)
- MBRX +12.4% (announced that the FDA has granted Rare Pediatric Disease Designation to its p-STAT3 inhibitor, WP1066, for the treatment of ependymoma)
- PRQR +4.7% (announces publication in Nature Medicine)
- NKLA +4.6% (Nikola Corporation IVECO and OGE announce intent to accelerate the deployment of hydrogen infrastructure and fueling solutions)
- TECH +3.7% (inked a license agreement for use of a proprietary Bio-Techne antibody by Xencor (XNCR))
- PFMT +3.4% (CMS awarded Performant an 8.5 year contract)
- MRNA +3.2% (provides clinical and supply updates on COVID-19 vaccines)
- MN +2.9% (reports March AUM of $21.1 bln)
- DNN +2.8% (announces discovery of high-grade uranium mineralization at mcclean lake south)
- GME +2.5% (announces voluntary early redemption of senior notes)
- AZN +1.7% (Tagrisso receives approval in China)
- DKNG +1.5% (DraftKings and PGA TOUR expand on existing commercial partnership)
- SQ +1.3% (extends Square Loans to Australia)
- VCTR +1% (reports March total AUM of $154.3 bln)
Analyst comments:
- FOLD +5.3% (upgraded to Overweight from Neutral at Cantor Fitzgerald)
- GLPG +4.3% (upgraded to Overweight from Equal Weight at Barclays)
- JBLU +3.1% (upgraded to Overweight from Underweight at JP Morgan)
- OXY +2.8% (upgraded to Buy from Neutral at MKM Partners)
- SAVE +2.3% (upgraded to Overweight from Underweight at JP Morgan)
- SNAP +2.2% (upgraded to Outperform from Neutral at Wedbush)
- FROG +0.9% (upgraded to Hold from Sell at Summit Insights)
- LOW +0.8% (upgraded to Overweight from Neutral at Atlantic Equities)